SARS-CoV-2 Antibodies and Antigens

InVivo has developed a large set of reagents for COVID-19 research and industrial-scale manufacturing of highly sensitive in vitro diagnostics kits. Our portfolio comprises different recombinant versions of the SARS-CoV-2 Spike protein, that were transiently expressed in our high-yielding mammalian HEK cells. These include the full-length Spike protein, the two functional subunits S1 and S2, plus the S1 receptor-binding domain (RBD). The antigens display great activity and proper glycosylation and are suitable for the development of highly sensitive immunoassays. To cater to long-term demand of bulk quantities in the gram scale, InVivo offers recombinant Spike antigen production from stable CHO cell pools.

The portfolio was recently expanded by several mutant Spike antigens of the recently discovered variants from UK, South Africa and Brazil. These antigens were produced via transient expression in our proprietary HEK system.

Additionally, we offer the SARS-CoV-2 Nucleocapsid protein from bacterial expression systems for research use as well.

For industry-scale manufacturing of SARS-CoV-2 detection kits (ELISA, Lateral Flow and more), InVivo provides different monoclonal antibodies from mouse hybridoma, which target the SARS-CoV-2 Spike or Nucleocapsid proteins, respectively. All Spike protein antibodies were validated by ELISA and demonstrate specificity for either the S1-subunit or the RBD region. Humanized chimeric recombinant antibodies targeting the Spike protein are still in development and will be available soon.

A) Schematic overview of the SARS-CoV-2 Spike (S) protein and its functional domains.

The S protein plays a crucial role in the infection process and is therefore a great target for the development of diagnostic assays. It is comprised of two subunits: S1 and S2.

The S1-subunit (aa 1-681) enables binding of the virion to the ACE2 receptor on the host cell membrane which initiates the infection. It contains an N-terminal signal peptide and the receptor-binding domain (RBD; aa 319-541) highlighted in grey.

The S2-subunit (aa 685-1273) contains a C-terminal transmembrane domain (TMD) and an endodomain. It mediates the fusion of the virion with the cellular membranes. The process of membrane fusion depends on S protein cleavage (Furin cleavage site, aa 682-685) leading to the activation of the S protein during infection.

B) Schematic overview of the SARS-CoV-2 Nucleocapsid (N) protein and its functional domains.

The SARS-CoV-2 Nucleocapsid (N) protein is the major structural component of the virion. It is involved in viral replication, assembly and immune regulation and plays key roles in the viral life cycle.

Both, the N-terminal Domain (NTD, aa 48–175) and the C-terminal Domain (CTD, aa 247–364), are capable of binding to the viral positive-sense, single-stranded RNA (+ssRNA). The CTD is furthermore responsible for the dimerization of the N protein. In between NTD and CTD lies an intrinsically disorder region (IDR), which interacts with the viral matrix protein (M), thus forming a physical connection between RNA genome and envelope.

SARS-CoV-2 Pipeline – ANTIGENS

Product-IDDescriptionStatus
NP_E.coli

Recombinant Nucleocapsid (N) protein (aa 1–419) with C-terminal deca-His-Tag, expressed in E. coli BL21(DE3). 1-step purification via IMAC to a purity of ≥90%.

Product Information

Available
S1-RBD_CHO

Recombinant Spike protein receptor binding domain (aa 319-541) with C-terminal hexa-His-Tag, stably expressed in CHO cell pools. 2-step purification via affinity chromatography and preparative SEC (polishing) to a purity ≥​ 90%.

Product Information

Available
Soluble Spike_CHO

Recombinant soluble Spike protein (aa 14-1213) stably expressed in CHO cell pools. The soluble Spike contains a mutated polybasic/ furin cleavage site, and mutations K986P/V987P for stabilization of the trimer. The C-terminal TMD and endodomain were replaced by a thrombin cleavage site, a trimerization site and a C-terminal hexa-His-Tag. 2-step purification via IMAC and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-RBD_HEK

Recombinant Spike protein receptor binding domain (aa 319-541) with C-terminal hexa-His-Tag, transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 2-step purification via IMAC and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-Subunit_HEK

Recombinant Spike protein S1-subunit (aa 14-681) with C-terminal hexa-His-Tag, transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 2-step purification via IMAC and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-Subunit-Fc_HEK

Recombinant Spike protein S1-subunit (aa 14-681) with C-terminal Fc-Tag, transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 2-step purification via IMAC and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S2-Subunit-Fc_HEK

Recombinant Spike protein S2-subunit (aa 685-1213; excluding TMD and endodomain) with C-terminal Fc-Tag, transiently expressed in InVivo’s proprietary optimized HEK-INV cells. 2-step purification via IMAC and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
Soluble Spike_HEK

Recombinant soluble Spike protein (aa 14-1213) transiently expressed in InVivo’s proprietary optimized HEK-INV cells. The soluble Spike contains a mutated polybasic/ furin cleavage site, and mutations K986P/V987P for stabilization of the trimer. The C-terminal TMD and endodomain were replaced by a thrombin cleavage site, a trimerization site and a C-terminal hexa-His-Tag. 2-step purification via IMAC and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available

SARS-CoV-2 Pipeline – MUTANT SPIKE ANTIGENS

Throughout the COVID-19 pandemic, several genetic variants of SARS-CoV-2 have emerged worldwide, which are classified as so-called variants of concern (VOC). Amongst other things, there is evidence for an increased transmissibility of these virus variants and a significant reduction of neutralization through existing antibodies. Many mutations affect the Spike protein and its receptor binding domain (RBD).

To investigate the influence of these mutations on the effectiveness of SARS-CoV-2 diagnostics, InVivo offers a series of mutant Spike antigens that were transiently expressed in high yielding mammalian HEK cells. These include the several Spike receptor-binding-domain mutants, such as the South African variant B.1.351, the Brazilian variant B.1.1.28.1 as well as two UK variants B.1.1.7 and B.1.1.7 (+E484K). Additionally, we also offer a mutant full-length Spike protein of the UK variant B.1.1.7.

Product-IDDescriptionStatus
Spike-B.1.1.7-UK_HEK

Spike protein of emerging UK B.1.1.7 SARS-COV-2 VOC-202012/01 (HV 69-70 del, Y144 del, N501Y, A570D, P681H, T716I, S982A, D1118H).

Protein design and manufacturing process is based on InVivo’s “Soluble Spike” protein (aa 14-1213). The C-terminal TMD and endodomain were replaced by a TEV cleavage site, a trimerization site and a C-terminal deca-His-Tag. 2-step purification via IMAC and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-RBD-B.1.1.7-UK_HEK

RBD of emerging UK B.1.1.7 SARS-COV-2 VOC-202012/01; mutation N501Y. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via IMAC and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-RBD-B.1.1.7-E484K-UK2_HEK

RBD of emerging UK B.1.1.7 SARS-COV-2 variant with additional immune-escape mutation E484K, N501Y VOC-202102/02. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via IMAC and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-RBD-B.1.351-SA_HEK

RBD of emerging South African B.1.351 SARS-COV-2 variant; mutations K417N, E484K, N501Y. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via IMAC and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available
S1-RBD- B.1.1.28.1-BR_HEK

RBD of emerging Brazilian B.1.1.28.1 SARS-COV-2 variant; mutations K417T, E484K, N501Y. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via IMAC and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

Available

S1-RBD-B.1.617.1-IN_HEK

 

RBD of emerging Indian B.1.617.1 SARS-COV-2 Variant of Interest VUI-21APR-01; mutations L452R, E484Q. Protein design and manufacturing process is based on InVivo’s RBD protein (aa 319-541) with C-terminal hexa-His-Tag, and 2-step purified via IMAC and preparative SEC (polishing) to a purity ≥ 90%.

Product Information

IN DEVELOPMENT

SARS-CoV-2 Pipeline – ANTIBODIES

InVivo offers a series of monoclonal antibodies for the detection of the Spike protein from SARS-CoV-2. These antibodies are produced from hybridoma cell lines that were generated by immunization with the recombinant Spike protein (SGP) or the receptor-binding domain (RBD). All antibodies were validated by ELISA; antibodies written in italics are specifically recommended for Sandwich-ELISA applications.

DescriptionProduct-IDSpecificityHostClonalityIsoptypeSubclassApplication

Anti-Spike (RBD) Antibody

Product Information

AK3399RBDMouseMonoclonalIgGmIgG2bκELISA

Anti-Spike (RBD) Antibody

Product Information

AK3400RBDMouseMonoclonalIgGmIgG2bκELISA

Anti-Spike (RBD) Antibody

Product Information

AK3401RBDMouseMonoclonalIgGmIgG2bκELISA

Anti-Spike (RBD) Antibody

Product Information

AK3403RBDMouseMonoclonalIgGmIgG1κ

ELISA

Sandwich-ELISA

AK3427+AK3403

Anti-Spike (RBD) Antibody

Product Information

AK3404RBDMouseMonoclonalIgGmIgG1κ

ELISA

Sandwich-ELISA

AK3404+AK3429

AK3404+AK3423

Anti-Spike (S1) Antibody

Product Information

AK3422 S1MouseMonoclonalIgGmIgG2aκELISA

Anti-Spike (S1) Antibody

Product Information

AK3423S1MouseMonoclonalIgGmIgG1κ

ELISA

Sandwich-ELISA

AK3404+AK3423

Anti-Spike (S1) Antibody

Product Information

AK3424S1MouseMonoclonalIgGmIgG2bκELISA

Anti-Spike (RBD) Antibody

Product Information

AK3426RBDMouseMonoclonalIgGmIgG1κELISA

Anti-Spike (RBD) Antibody

Product Information

AK3427RBDMouseMonoclonalIgGmIgG1κ

ELISA

Sandwich-ELISA

AK3427+AK3403

Anti-Spike (S1) Antibody

Product Information

AK3429S1MouseMonoclonalIgGmIgG1κ

ELISA

Sandwich-ELISA

AK3404-AK3429

 

Products in Development

DescriptionProduct-IDSpecificityHostClonalityIsoptypeSubclassStatus
Anti-NP AntibodyAK3454NPMouseMonoclonalIgGTBAIN DEVELOPMENT
Anti-Spike (RBD) rec AntibodyRP_SZ_824RBDMammalianNAHuman IgGTBAIN DEVELOPMENT
Anti-Spike (S1) rec AntibodyRP_SZ_828S1MammalianNAHuman IgGTBAIN DEVELOPMENT

 

InVivo also offers custom solutions for the production of other Coronavirus antigens. If none of the products mentioned above are of your interest, please reach out to us and learn about production capacities and timelines for your protein of choice.

Contact Us

Invivo Biotech Services

Neuendorfstr. 24a
16761 Hennigsdorf
Germany

email_subscribe_callback

GDPR

8 + 6 =